A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

Recruiting

Phase 1

CMV-MVA TriplexA Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

Sponsor:

City of Hope Medical Center

Code:

NCT07020533

Conditions

Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia

Chronic Lymphocytic Leukemia

Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

Biospecimen Collection

Electronic Health Record Review

Haploidentical Hematopoietic Cell Transplantation

Letermovir

Multi-peptide CMV-Modified Vaccinia Ankara Vaccine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-06. This information was provided to ClinicalTrials.gov by City of Hope Medical Center on 2026-03-27.